Investment Rating - The report maintains a "Buy" rating for key companies in the pharmaceutical and biotechnology sector, including WuXi AppTec, WuXi Biologics, and Changchun High-tech [5][28]. Core Insights - The report expresses a strong outlook on the innovation theme and emphasizes the importance of capturing Q3 performance. The pharmaceutical sector has shown a decline, with the Shanghai Composite Index down 2.73% and the pharmaceutical sector down 3.65% [12][16]. - The report highlights the active participation of Chinese biopharmaceutical companies in global business development (BD) transactions, which have reached 38% of the global total since 2025. This trend is expected to boost investment sentiment in the sector [12][16]. - The report suggests focusing on companies with improving performance metrics, particularly in the CRO/CDMO and upstream segments, as well as in medical devices and traditional Chinese medicine [12][16]. Summary by Sections Industry Overview - The pharmaceutical industry comprises 515 listed companies with a total market capitalization of approximately 731.59 billion yuan and a circulating market value of about 666.30 billion yuan [2]. Market Dynamics - The pharmaceutical sector has experienced a year-to-date return of 18.85%, outperforming the Shanghai Composite Index by 4.13 percentage points. However, recent weeks have seen a decline in various sub-sectors, with traditional Chinese medicine being the only one to show an increase [16][18]. Valuation Metrics - The current valuation of the pharmaceutical sector is approximately 26.2 times PE based on 2025 earnings forecasts, which is a premium of 17.3% compared to the overall A-share market (excluding financials). The TTM valuation stands at 30.1 times PE, below the historical average of 34.9 times PE [18][20]. Key Company Performance - The report lists several companies with strong performance metrics, including WuXi AppTec, WuXi Biologics, and Changchun High-tech, all rated as "Buy." The average decline for recommended stocks in the month was 10.08%, with a weekly decline of 7.43% [28][29]. Business Development Activity - The report notes that several pharmaceutical companies have engaged in overseas licensing agreements, indicating a growing recognition of Chinese companies' capabilities in the global market [12][16]. Regulatory Updates - Recent regulatory announcements from the National Medical Insurance Administration and the National Medical Products Administration are aimed at improving drug pricing transparency and enhancing the approval process for innovative drugs [12][29]. Price Trends - The report tracks the price movements of various vitamins, noting slight decreases in some and stability in others, which may impact the cost structure for companies in the sector [31][32].

Investment Rating - The report maintains an investment rating of "Outperform" for the biopharmaceutical sector [8]. Core Insights - The report highlights several catalysts for the sector, including academic conferences, business development (BD) achievements, medical insurance negotiations, and innovative drug directories from commercial insurance [21]. - Key companies to watch include: 1. Products with high certainty for overseas expansion certified by MNCs: PD-1 upgraded products from Sanofi and GLP-1 assets from Federal Pharmaceuticals [21]. 2. Potential blockbuster products for overseas licensing from MNCs: PD-1 upgraded products from Kangfang Biotech and Innovent Biologics, breakthroughs in autoimmune fields from Yifang Biotech and China Antibody, and innovative target ADCs from Fuhong Hanlin and Shiyao Group [21]. 3. Companies likely to benefit from medical insurance negotiations and innovative drug directories: Heng Rui Medicine, Kangnuo Pharmaceutical, Maiwei Biotech, Zhixiang Jintai, and Haichuang Pharmaceutical [21]. Summary by Sections Weekly New Drug Market Review - From October 13 to October 19, 2025, the top five gainers in the new drug sector were: - Sanofi National Health (+12.68%) - Kangning Jereh (+10.18%) - Rongchang Biotech (+5.42%) - Xiansheng Pharmaceuticals (+4.88%) - Qianyan Biotech (+3.77%) - The top five losers were: - Yongtai Biotech (-29.76%) - Betta Pharmaceuticals (-16.98%) - Yiming Oncology (-16.80%) - Deqi Pharmaceuticals (-15.30%) - WuXi Biologics (-13.43%) [4][16]. New Drug Industry Focus Analysis - Recently, Bai Li Tianheng presented overseas multi-center solid tumor research data for its EGFR×HER3 dual antibody ADC drug, iza-bren, at the 2025 European Society for Medical Oncology (ESMO) annual meeting. The data showed consistent efficacy and safety across different populations, confirming the broad-spectrum tumor-killing efficacy of iza-bren [21][24]. New Drug Approval and Acceptance - This week, one new drug or new indication application was approved, and 13 new drug or new indication applications were accepted in China [9][27]. - Additionally, 30 new drug clinical applications were approved, and 47 new drug clinical applications were accepted [10][30].

Investment Rating - The report maintains a "Positive" investment rating for the insulin industry [10] Core Insights - The insulin market is stabilizing post-collection procurement, with companies focusing on innovation and steady progress in R&D pipelines, creating a closed-loop advantage in insulin, diabetes, endocrine, and metabolism sectors [3][9] - The progress of insulin exports is promising, expected to contribute to new growth [8] - The cash flow of companies is gradually stabilizing, and the valuation of innovative pipelines is likely to be reshaped [9] Summary by Sections Domestic Insulin Collection Procurement - The domestic insulin market is broad, with insulin analogs becoming the main driving force. In 2021, there were approximately 14.1 million diabetes patients in China, with an expected increase to 29.3 million by 2030. The market size for insulin in China is projected to be 22.3 billion yuan in 2024, reflecting a year-on-year decrease of 14.23% [20] - The first round of national collection procurement was moderate, ensuring basic procurement volume and expanding external market channels. Nearly 50% of the insulin market share was not included in the procurement, allowing leading companies to significantly increase sales volume [27][20] - The second round of procurement renewal has seen price increases for some companies, reflecting a balanced approach by the National Medical Insurance Administration [30][27] Insulin Export Progress - Companies like Ganli Pharmaceutical and Tonghua Dongbao are making significant progress in exporting insulin to developed regions like Europe and the US, where the insulin market is valued at $13.2 billion. The market in developing regions such as Asia, Africa, and Latin America is estimated to be between $4.3 billion and $6.5 billion [8][20] Innovative Drug Pipeline - The innovative drug pipeline is gradually yielding results, with a focus on GLP-1 research and development. Insulin companies are expected to leverage their advantages in sales terminals, process development, and production capacity in the GLP-1 sector [9][8] - The management teams and innovation systems of these companies are undergoing significant changes, which may lead to a reshaping of their valuations [9]

Core Viewpoint - The Hong Kong stock market is experiencing a weak consolidation, with the Hang Seng Index slightly down by 0.09%. However, the Hong Kong Stock Connect innovative drug sector has shown resilience, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising by 2.42% after a brief surge earlier in the day, indicating potential bullish momentum in the sector [1][2]. Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has successfully rebounded, recovering its 5-day moving average with a trading volume increase of over 65% to 619 million yuan, showcasing strong bullish sentiment [1]. - Since mid-September, the innovative drug sector has been in a downward trend, but recent rebounds suggest a possible turning point, driven by significant capital inflows into key stocks [2][3]. Upcoming Catalysts - The upcoming European Society for Medical Oncology (ESMO) annual meeting on October 17 is expected to be a major catalyst, with the release of clinical data for Chinese innovative drugs likely to attract market attention [3]. - Future performance in the innovative drug sector may depend on several factors, including the disclosure of Q3 earnings reports, the traditional peak season for business development (BD) transactions in October-November, and the national medical insurance negotiations in November [3]. Investment Focus - Analysts suggest that the focus in the innovative drug sector is shifting from broad valuation recovery to the fundamental performance of companies, emphasizing the importance of strong clinical data, commercialization capabilities, and potential for international expansion [3]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) tracks 37 innovative drug companies, with significant gains in major weighted stocks such as Innovent Biologics, CanSino Biologics, and 3SBio [4][5]. Index Performance - The Hang Seng Stock Connect Innovative Drug Select Index has shown higher elasticity and stronger offensive capability compared to similar indices, with a year-to-date increase of 108.14% as of the end of September [6][7].

智傲控股 （除权日） 百盛集团 （派息日） 东方海外国际 （派息日） 康耐特光学 （派息日） S.A.S. DRAGON （派息日） 股本增发 智通财经APP获悉，2025年10月15日，港股上市公司投资日志如下： | 类别 | | 公司 | | --- | --- | --- | | | 广和通 | | | | (招股中) | | | | 聚水潭 | | | | (招股中) | | | 新股活动 | 海西新药 | | | | (定价日) | | | | 轩竹生物-B | | | | (上市日) | | | 业绩公布日 | 中国来骑哦 | | | | 瓦普思瑞元宇宙 智昇集团控股 | | | | 云南水务 | | | | 华控康泰 | | | | 天臣控股 | | | 股东大会召开日 | 龙皇集团 | | | | 康宁医院 | | | | 健世科技-B | | | | 中泽丰 | | | | 海纳星空科技 | | | | 嘉进投资国际 | | | 停复牌 | （复牌） | | | 分红派息 | AEON CREDIT | | | | （除净日） | | | | 上海实业控股 | | | | （派息日） | | ...

Summary of Conference Call Notes Industry Overview - The focus remains on the innovative drug sector, benefiting from business development (BD) transactions and data catalysts, with companies like Heng Rui continuing to push forward despite recent large transactions not meeting expectations [1][2] - The CRO (Contract Research Organization), CDMO (Contract Development and Manufacturing Organization), and upstream supply chain are benefiting from anticipated interest rate cuts in the U.S. and recovering order performance [1][2] - Medical devices, particularly high-consumption and equipment sectors, are showing signs of reversing performance difficulties, with Q3 expected to show improvement [1][2] Key Investment Strategies - Emphasis on the innovative drug line, with catalysts from the ESMO conference and BD transactions, alongside Q3 performance improvements [1][5] - Attention to the impact of basic drug directory policies and adjustments in traditional Chinese medicine companies, which may provide short-term catalysts [1][5] - Portfolio adjustments in October 2025 included increasing positions in companies like Changchun High-tech, Xianju Pharmaceutical, Betta Pharmaceuticals, and Tengke Pharmaceuticals, as well as companies showing performance inflection points [1][6] Core Recommendations - Recommended stocks based on three criteria: vertical extension capability in the supply chain, realization capability, and systematic early-stage R&D platform capability [9] - Specific recommendations include Changchun High-tech, Betta Pharmaceuticals, Amgen Pharmaceuticals, and Xiansheng Pharmaceuticals [9] - Notable mentions include Amgen, WuXi Biologics, and Miaomei Helian, expected to benefit from strong Taiji business, recovery in monoclonal antibody business, and high growth in ADC projects, with significant earnings growth anticipated in 2025 [1][19] Sector-Specific Insights - The innovative drug sector is viewed as the strongest and most fundamentally sound segment, with a focus on recovery from previous difficulties and policy changes [3][4] - CROs are showing early signs of recovery, with significant performance from WuXi and similar companies [3][4] - Medical devices are also recovering, with various companies performing well across different segments [4] Company-Specific Developments - **Betta Pharmaceuticals**: Notable for strong financial performance and ongoing business development, including an IPO process in Hong Kong expected to bring positive momentum [10] - **Amgen Pharmaceuticals**: Recently introduced strategic investment from Haizheng Pharmaceuticals, enhancing future growth prospects [11] - **Miaomei Helian**: Positioned as a leader in the ADC CRDMO sector, with significant growth expected from backend projects [20] - **Tianyu Co.**: Anticipated to maintain strong growth due to a diverse product pipeline and CDMO business expansion [25] - **Lianbang Pharmaceuticals**: Focused on innovative drugs, with several promising projects in clinical trials expected to drive future growth [26][27] Market Performance - The recommended portfolio showed an average increase of 5.5 percentage points in September, outperforming the broader pharmaceutical sector by 7.2 percentage points [6] - Specific stocks like Changchun High-tech and WuXi Biologics saw significant price increases of 26% and 23%, respectively [6] Conclusion - The innovative drug sector remains a key focus for investment, with several companies showing promising signs of recovery and growth potential. The overall sentiment is positive, with expectations for continued performance improvements in Q3 and beyond, driven by strategic investments and favorable market conditions [1][2][5]

Core Viewpoint - The company, 联邦制药, announced a mid-term dividend of HKD 0.17507 per share, which will be distributed on October 15, 2025, for the six months ending June 30, 2025 [1] Group 1 - The mid-term dividend is set at HKD 0.17507 per share [1] - The dividend distribution date is scheduled for October 15, 2025 [1] - The dividend pertains to the financial period ending June 30, 2025 [1]

Group 1 - The company, 联邦制药 (03933), announced a mid-term dividend of HKD 0.17507 per share, which will be distributed on October 15, 2025 [1] - The dividend pertains to the six-month period ending June 30, 2025 [1]

EF001 發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 董事會成員包括執行董事：蔡海山先生、梁永康先生、蔡紹哲女士、方煜平先生、鄒鮮紅女士及朱蘇燕女士；以及獨立非執行董 事：張品文先生、宋敏教授及傅秋實博士 第 2 頁 共 2 頁 v 1.1.1 第 1 頁 共 2 頁 v 1.1.1 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 聯邦制藥國際控股有限公司 | | 股份代號 | 03933 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二五年六月三十日止六個月中期股息 | | 公告日期 | 2025年8月28日 | | 公告狀態 | 更新公告 | | 更新/撤回理由 | 公告兌換 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 The United Laboratories International Holdings Limited 聯邦制藥國際控股有限公司 ( 於開曼群島註冊成立的有限公司 ) (股份代號 : 3933) 茲提述聯邦制藥國際控股有限公司（「本公司」）日期為二零二五年八月二十八日的公告，其 中包括宣派截至二零二五年六月三十日止六個月的中期股息每股人民幣16分。 應派發給股東的中期股息將折算為港幣支付。以兌換匯率人民幣1.00元相當於港幣1.094190元 計算，中期股息將以每股港幣0.175070元派發。 預期中期股息將於二零二五年十月十五日派發予於二零二五年九月三十日名列本公司股東名 冊的股東。 承董事會命 聯邦制藥國際控股有限公司 主席 蔡海山 香港，二零二五年十月二日 於本公告日期，董事會成員包括執行董事：蔡海山先生、梁永康先生、蔡紹哲女士、方煜平 先生、鄒鮮紅女士及朱蘇燕女士；以及獨立非執行董事：張品 ...